Featured Publications
Global Perspective on the Impact of the COVID‐19 Pandemic on Rheumatology and Health Equity
Hsieh E, Dey D, Grainger R, Li M, Machado P, Ugarte‐Gil M, Yazdany J. Global Perspective on the Impact of the COVID‐19 Pandemic on Rheumatology and Health Equity. Arthritis Care & Research 2023, 76: 22-31. PMID: 37277949, DOI: 10.1002/acr.25169.Peer-Reviewed Original ResearchConceptsRheumatic diseasesRheumatology practiceHealth service useHealth care utilizationCOVID-19 morbidityHealth care accessCOVID-19 pandemicMental health outcomesUptake of telemedicinePublic health emergencyPublic health communicationAcute phaseVaccine uptakeCare utilizationVaccination practicesRapid guidelinesWorse diseaseCare accessService useHealth outcomesPatient careDiseaseHealth equityHealth emergencyPandemic wanesSARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
Conway R, Grimshaw AA, Konig MF, Putman M, Duarte‐García A, Tseng LY, Cabrera DM, Chock YPE, Degirmenci HB, Duff E, Egeli BH, Graef ER, Gupta A, Harkins P, Hoyer BF, Jayatilleke A, Jin S, Kasia C, Khilnani A, Kilian A, Kim AHJ, Lin CMA, Low C, Proulx L, Sattui SE, Singh N, Sparks JA, Tam H, Ugarte‐Gil M, Ung N, Wang K, Wise LM, Yang Z, Young KJ, Liew JW, Grainger R, Wallace ZS, Hsieh E, Alliance T. SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis. Arthritis & Rheumatology 2022, 74: 766-775. PMID: 34807517, PMCID: PMC9011807, DOI: 10.1002/art.42030.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionMechanical ventilationRisk ratioOdds ratioMortality rateCOVID-19 disease severityJoanna Briggs Institute critical appraisal toolsCOVID-19Odds of hospitalizationNewcastle-Ottawa ScaleCOVID-19 outcomesRandom-effects modelCritical appraisal toolMantel-Haenszel formulaSystematic literature reviewAdjusted riskICU admissionRMD patientsClinical outcomesRheumatic diseasesMethodologic qualityRelative riskObservational studyGeneral populationLower risk
2024
The Association Between Rheumatic Disease Therapies and Cardiovascular Outcomes in People with HIV—A Retrospective Cohort Study
Titanji B, Nagatomi S, Gallini J, Cui X, Hanberg J, Hsieh E, Marconi V. The Association Between Rheumatic Disease Therapies and Cardiovascular Outcomes in People with HIV—A Retrospective Cohort Study. Journal Of Clinical Medicine 2024, 13: 6209. PMID: 39458159, PMCID: PMC11508247, DOI: 10.3390/jcm13206209.Peer-Reviewed Original ResearchRisk of CVD eventsElectronic health recordsCardiovascular disease eventsCVD eventsRetrospective cohort studyCardiovascular diseaseCohort studyIncidence of CVD eventsIncreased risk of CVD eventsRheumatic diseasesCardiovascular disease outcomesCardiovascular disease riskRisk of cardiovascular diseaseHealth recordsAssociated with increased CVD eventsGeneral populationPrimary outcomeDisease therapyAtlanta VAMCIncreased riskHIV infectionExacerbated inflammationCardiovascular outcomesPatient populationHIV
2022
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regression
2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritis